Abstract
Background & Aim: Interferon-free DAA combinations allow an effective treatment of HCV recurrence after orthotopic liver transplantation (OLT), but the role of ribavirin (RBV) in the post transplant setting is still under debate. So far published data gained from IFN/RBV-free DAA-based regimens are sparse. We thus aimed to analyze safety and efficacy of IFN/RBV-free DAA-based regimens in HCV-recurrence after OLT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
